Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association
Reads0
Chats0
TLDR
Although no prospective trial has yet been completed to evaluate the clinical significance of these serum markers, this literature survey suggests that combinations of CEA, CA19-9, and CA72-4 are the most effective ways for staging before surgery or chemotherapy.Abstract:
The aim of this review was to evaluate the clinical significance of serum tumor markers, particularly CEA, CA19-9, and CA72-4, in patients with gastric cancer. A systematic literature search was performed using PubMed/MEDLINE with the keywords “gastric cancer” and “tumor marker,” to select 4,925 relevant reports published before the end of November 2012. A total of 187 publications contained data for CEA and CA19-9, and 19 publications contained data related to all three tumor markers. The positive rates were 21.1 % for CEA, 27.8 % for CA19-9, and 30.0 % for CA72-4. These three markers were significantly associated with tumor stage and patient survival. Serum markers are not useful for early cancer, but they are useful for detecting recurrence and distant metastasis, predicting patient survival, and monitoring after surgery. Tumor marker monitoring may be useful for patients after surgery because the positive conversion of tumor markers usually occurs 2–3 months before imaging abnormalities. Among other tumor markers, alpha-fetoprotein (AFP) is useful for detecting and predicting liver metastases. Moreover, CA125 and sialyl Tn antigens (STN) are useful for detecting peritoneal metastases. Although no prospective trial has yet been completed to evaluate the clinical significance of these serum markers, this literature survey suggests that combinations of CEA, CA19-9, and CA72-4 are the most effective ways for staging before surgery or chemotherapy. In particular, monitoring tumor markers that were elevated before surgery or chemotherapy could be useful for detection of recurrence or evaluation of the response.read more
Citations
More filters
Journal ArticleDOI
Using circular RNA hsa_circ_0000190 as a new biomarker in the diagnosis of gastric cancer.
TL;DR: It is indicated that hsa_circ_0000190 may be a novel non-invasive biomarker for the diagnosis of gastric cancer and its AUC, sensitivity and specificity are better than commonly used biomarkers such as CEA and CA19-9.
Journal ArticleDOI
Biomarkers of gastric cancer: Current topics and future perspective.
Tasuku Matsuoka,Masakazu Yashiro +1 more
TL;DR: The current status and approaches in GC biomarker are summarized, which could be potentially used for early diagnosis, accurate prediction of therapeutic approaches and the future perspective based on the molecular classification and profiling is discussed.
Journal ArticleDOI
Recent advances in gastric cancer early diagnosis.
Laura Necula,Lilia Matei,Denisa Dragu,Ana Iulia Neagu,Cristina Mambet,Saviana Nedeianu,Coralia Bleotu,Carmen C. Diaconu,Mihaela Chivu-Economescu +8 more
TL;DR: The recently discovered circulating molecules such as microRNAs, long non-coding RNAs, circular RNas, which hold the promise to develop new strategies for early diagnosis of GC are summarized.
Journal ArticleDOI
Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification
TL;DR: The provision of conversion therapy for stage IV GC patients might be one of the main roles of surgical oncologists in the near future.
Journal ArticleDOI
Exosomal long noncoding RNA HOTTIP as potential novel diagnostic and prognostic biomarker test for gastric cancer
TL;DR: Exosomal HOTTIP may be a potential biomarker for GC in diagnosis and prognosis and was an independent prognostic factor in GC patients.
References
More filters
Journal ArticleDOI
Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma.
Daniele Marrelli,Franco Roviello,Alfonso De Stefano,Maurizio Farnetani,Lorenzo Garosi,Angelo Messano,Enrico Pinto +6 more
TL;DR: The combined assay of CEA, CA 19-9 and CA 72-4 preoperative serum levels provides additional prognostic information in patients resected for gastric cancer; patients with preoperative positivity for one of these tumor markers should be considered at high risk of recurrence even in early stages of gastric carcinoma.
Journal ArticleDOI
The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study
Yutaka Takahashi,Takeuchi T,Junichi Sakamoto,Tetsuya Touge,Masayoshi Mai,Hisanao Ohkura,Susumu Kodaira,Kunio Okajima,Hiroaki Nakazato +8 more
TL;DR: It is suggested that CEA and/or CA19-9 monitoring after operation was useful to predict the recurrence of gastric cancer, especially in almost all the patients with high preoperative levels of these markers.
Journal ArticleDOI
Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer
Daniele Marrelli,Enrico Pinto,Alfonso De Stefano,Maurizio Farnetani,Lorenzo Garosi,Franco Roviello +5 more
TL;DR: The combined assay of CEA, CA 19-9, and CA72-4 may be useful for early diagnosis of recurrence of gastric cancer; however, only CA 72-4 positivity should be considered a specific predictor of tumor recurrence.
Journal ArticleDOI
Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer
TL;DR: It is suggested that high preoperative serum levels of CA 72-4 in gastric cancer patients are associated with a higher risk of death due to Gastric cancer.
Journal ArticleDOI
Clinicopathologic features and prognostic factors in alpha‐fetoprotein‐producing gastric cancers: Analysis of 104 cases
TL;DR: The aim of this study was to elucidate the clinicopathologic characteristics and prognostic factors of alpha‐fetoprotein (AFP)‐producing gastric cancer.